Novel oncolytic herpes simplex virus 1 VC2 promotes long-lasting, systemic anti-melanoma tumor immune responses and increased survival in an immunocompetent B16F10-derived mouse melanoma model

Authors

I.K. Uche
N. Fowlkes
L. Vu
T. Watanabe
M. Carossino
R. Nabi
F. del Piero
J.S. Rudd
K.G. Kousoulas
P.J.F. Ridera

Document Type

Article

Publication Date

1-1-2021

Publication Source (Journal or Book title)

Journal of Virology

Recommended Citation

Uche, I., Fowlkes, N., Vu, L., Watanabe, T., Carossino, M., Nabi, R., del Piero, F., Rudd, J., Kousoulas, K., & Ridera, P. (2021). Novel oncolytic herpes simplex virus 1 VC2 promotes long-lasting, systemic anti-melanoma tumor immune responses and increased survival in an immunocompetent B16F10-derived mouse melanoma model. Journal of Virology, 95 (3) https://doi.org/10.1128/JVI.01359-20